NASDAQ : ENTX
Entera Bio Ltd. — Key statistics
Healthcare · Biotechnology · Israel
Last price 3.2 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 556.55M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 556.55M |
| Enterprise Value | 545.67M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 13, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 173.92M |
| Shares Outstanding | 173.92M |
| Shares Change (YoY) | +15.33% |
| Shares Change (QoQ) | +5.64% |
| Owned by Insiders (%) | 0.88% |
| Owned by Institutions (%) | 13.25% |
| Float | 118.29M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 21.71 |
| P/TBV Ratio | 76.60 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 8.98 |
| Quick Ratio | 5.42 |
| Debt / Equity | 0.06 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.30 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -138.92% |
| Return on Assets (ROA) | -45.98% |
| Return on Invested Capital (ROIC) | -71.57% |
| Return on Capital Employed (ROCE) | -82.87% |
| Weighted Average Cost of Capital (WACC) | 12.64% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$774,227 |
| Employee Count | 22 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 1.46 |
| 52-Week Price Change | +17.22% |
| 50-Day Moving Average | 2.90 |
| 200-Day Moving Average | 1.91 |
| Relative Strength Index (RSI) | 63.63 |
| Average Volume (20 Days) | 644,714 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 5.55M |
| Short Previous Month | 2.40M |
| Short % of Shares Out | 3.19% |
| Short % of Float | 4.69% |
| Short Ratio (days to cover) | 9.01 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -14.40M |
| Pretax Income | -17.03M |
| Net Income | -17.03M |
| EBITDA | -14.37M |
| EBIT | -14.40M |
| Earnings Per Share (EPS) | -$0.35 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 11.31M |
| Total Debt | 425,000 |
| Net Cash | 10.88M |
| Net Cash Per Share | $0.06 |
| Equity (Book Value) | 7.27M |
| Book Value Per Share | 0.15 |
| Working Capital | 16.79M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -10.89M |
| Capital Expenditures | -73,000 |
| Depreciation & Amortization | 31,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -10.96M |
| FCF Per Share | -$0.06 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -15.33% |
| Shareholder Yield | n/a |
| Earnings Yield | -11.05% |
| FCF Yield | -1.97% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $9.75 |
| Price Target Difference | 204.69% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -7.26 |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |